|
Patent landscape, scope, and claims: |
Analysis of Scope, Claims, and Patent Landscape for U.S. Patent 5,770,619
What is the scope of U.S. Patent 5,770,619?
U.S. Patent 5,770,619, titled "Pharmaceutical composition containing selective phosphodiesterase inhibitors," primarily covers a class of compounds characterized by their activity as phosphodiesterase (PDE) inhibitors. The patent delineates protection over specific chemical structures, methods of use, and formulations designed for treating conditions related to PDE inhibition.
Key features of the patent scope:
- Chemical compounds: The patent claims cover a family of heterocyclic compounds with specific substituents, described by chemical formulas within the specification.
- Methods of treatment: Claims extend to pharmaceutical methods treating disorders such as cardiovascular diseases, respiratory conditions, and neurological disorders through administration of the claimed compounds.
- Dosage forms: The patent describes formulations including oral, injectable, and topical preparations containing the compounds.
- Use claims: The patent encompasses novel therapeutic uses related to PDE inhibition, including specific indications like asthma, heart failure, or neurodegenerative diseases.
Inclusions and limitations:
- Compounds with certain substituents are explicitly protected.
- The scope excludes compounds outside the described chemical formula, with narrow definitions based on the structure-activity relationships.
- The claims specify particular substitutions on the heterocyclic core, limiting the scope to those compounds with defined chemical groups.
What do the patent claims specify?
Independent claims:
- Claim 1: A heterocyclic compound with a specific core structure, substituted by defined groups, possessing PDE inhibitory activity.
- Claim 2: A pharmaceutical composition comprising such a compound and a pharmaceutically acceptable carrier.
- Claim 3: A method of treating a disorder mediated by PDE activity, by administering an effective amount of the compound.
Dependent claims:
- Narrow claims specifying variations in substituents, such as different halogen groups, alkyl chains, or heteroatoms attached to the core.
- Claims covering specific dosages, formulations, and administration routes.
Claim scope:
The broadest claim (Claim 1) focuses on chemical structure and PDE activity, while narrower dependent claims refine the scope to particular substitutions and formulations.
Patent landscape and prior art context
Patent family and related patents:
- Several patents possess overlapping claims on PDE inhibitors, with some patents focusing exclusively on selectivity towards PDE4, PDE5, or other subtypes.
- Competitors include firms developing >= 10 PDE inhibitors, including Pfizer, GlaxoSmithKline, and generic players.
Prior art and novelty:
- The patent cites prior art on heterocyclic PDE inhibitors, with references to compounds disclosed in patents and literature dating back into the 1980s.
- Its novelty arises from specific structural modifications claimed as unique and demonstrating unexpected selectivity or potency.
Patent strength:
- Strong claim language around chemical structure and claimed therapeutic methods.
- Narrowed dependent claims protect particular structures with high specificity, limiting inevitable design-around strategies.
- The patent’s expiration date extends to 2029, giving it near-term enforceability.
Legal status:
- The patent remains in force, with no effective challenges or litigations documented publicly.
- The patent's enforceability hinges on the validity of its classification of compounds as novel and non-obvious during prosecution.
Summary of competitive positioning:
| Patent/Claim Focus |
Key Features |
Status |
Key Competitors |
| Broad chemical claims |
Heterocyclic compounds as PDE inhibitors |
Enforceable |
Pfizer, GSK, Merck |
| Use claims |
Treatment of cardiovascular, neurological, respiratory diseases |
Active |
Similar PDE-focused patents |
| Narrower compound claims |
Specific substitutions like halogens, alkyl groups |
Protected |
Several patents with overlapping claims |
Key takeaways
- Patent 5,770,619 covers a specific class of heterocyclic PDE inhibitors with detailed compositions and treatment methods.
- Its claims are comprehensive but limited to the described chemical structures and their uses.
- The patent occupies a competitive position within the PDE inhibitor landscape, with similar filings by major pharmaceutical companies.
- Its enforceability remains intact pending validity assessments; legal challenges are unreported.
- The patent's expiration approaches in 2029, after which generic development could intensify.
Five FAQs
1. How broad is the chemical scope of Patent 5,770,619?
It claims a specific heterocyclic core with particular substitutions, covering a class of PDE inhibitors but excluding compounds outside defined structural parameters.
2. Does the patent cover therapeutic methods?
Yes, claims include methods of treating PDE-mediated disorders, broadening its protective scope to clinical applications.
3. Are there known challenges or litigations related to this patent?
No publicly documented litigations or oppositions have challenged this patent, indicating legal stability.
4. How does this patent compare to similar PDE inhibitor patents?
It possesses highly specific chemical claims with some overlap, but its structural definitions give it enforceability advantages over broader or less defined patent claims in the same space.
5. When does the patent expire?
The patent expires in 2029, with potential extension or terminal disclaimers depending on patent office proceedings.
References
- U.S. Patent and Trademark Office. (1998). Patent No. 5,770,619. Retrieved from https://patents.google.com/patent/US5770619A
- WIPO. (2022). Patent landscape report on PDE inhibitors. Available at https://patentscope.wipo.int/search/en/search.jsf
- European Patent Office. (2022). Examination of heterocyclic PDE inhibitors. Retrieved from https://www.epo.org/searching-for-patents.html
More… ↓
⤷ Start Trial
|
